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Introduction
Acute lung injury (ALI) is a clinical syndrome charac-
terized by impairment in gas exchange and/or lung 
mechanics that leads to hypoxemia and increased work 
of breathing (WOB). When respiratory failure occurs, 
most patients require mechanical ventilation. Th is clinical 
scenario is related to high morbidity and mortality rates.
Th ere have been large amounts of research on the 
patho genetic mechanisms of lung injury, which include 
changes in alveolocapillary permeability, the inﬂ amma-
tory response, extracellular matrix remodeling and ab-
normal alveolar micromechanics. In spite of this know-
ledge, no eﬀ ective therapy, other than treating the initial 
cause of injury and providing supportive treatment, has 
been shown to have a signiﬁ cant clinical beneﬁ t. Fortu-
nately, the cause of ALI is known in most cases, so 
speciﬁ c therapy can be initiated (e.g., antibiotics in sepsis, 
surgery when appropriate). In other cases, the cause is 
time-limited, such as in aspiration pneumonitis or poly-
trauma. However, even in these cases, ALI may persist 
beyond the initial insult. In this setting, restoration of 
normal lung structure and function is of paramount 
importance for survival.
Th ere is increasing evidence of the lung’s capacity to 
repair itself. Th is process involves an interplay between 
various cellular and molecular mechanisms, including 
resolution of edema and inﬂ ammation, cell proliferation 
and tissue remodeling. Moreover, it is possible that some 
of these mechanisms, activated early in the response to 
injury, are essential for normal repair later on. With this 
in mind, timing of a therapeutic intervention becomes a 
critical issue, as blockade of one mediator may prevent 
injury when administered early, but also impair the repair 
phase. Moreover, strategies aimed at promoting repair 
could represent a new alternative for patients with ALI.
Knowledge of the repair mechanisms could, therefore, 
be the next step to understanding the lung response to 
injury. In this review, we will summarize some of these 
mechanisms and discuss their relevance as potential 
therapeutic targets in ALI.
An overview of the repair process
Th e lung response to an injurious stimulus involves 
transduction of the danger signal into a biochemical 
response. Depending on the cause, there are many 
pathways that can be activated. For instance, bacterial 
antigens may trigger an inﬂ ammatory response by 
activating any of the Toll-like receptors (TLR). Chemical 
agents induce cell membrane damage and, in some cases, 
oxidative stress, leading to the activation of a number of 
intracellular kinases. Mechanical stress, such as positive 
pressure ventilation, can also precipitate a biological 
response after a mechanotransduction process [1].
In addition to exogenous causes, an endogenous system 
detects tissue and cell damage and triggers the physio-
logical response. Alarmins, a subgroup of molecules of a 
larger set called DAMPs (damage-associated molecular 
patterns), lead to this system. Structurally diﬀ erent, these 
endogenous molecules are released in response to tissue 
damage by dead cells and local inﬂ ammatory cells 
(alveolar macrophages in the case of lung), activating and 
recruiting immune cells through binding to diﬀ erent 
receptors, such as TLR, interleukin-1 receptor (IL-1R) 
and RAGE (receptor of advanced glycation end-products)
[2], thereby activating the pro-inﬂ ammatory pathway. 
Irrespective of the cause, these signals converge in a 
group of transcription factors (e.g., nuclear factor-kappa 
B [NF-κB], activator protein [AP]-1), which induce the 
synthesis of new molecules that ultimately mediate the 
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inﬂ ammatory response to the aggression. Hallmarks of 
this response are the increased alveolocapillary permea-
bility, which causes a protein-rich edema, the neutrophil 
inﬁ ltrate (recruited from the circulation in response to 
chemokines), and the release of a wide variety of media-
tors, such as cyto- and chemokines, proteases, eicosa-
noids and growth factors, into the extracellular space. 
Figure  1 summarizes this process. During this stage, 
pneumocyte death due to apoptosis (in response to 
released mediators) and/or necrosis (caused by toxins, 
proteases...) results in exposure of the basement mem-
brane of the alveolar epithelium.
One of the key steps in the tissue response is the 
deposition of collagen ﬁ bers at the sites of injury. Simi-
larly to what happens in skin wounds, lung ﬁ bro blasts 
release procollagen peptides into the extracellular space, 
in order to create a scar. Th is is probably an attempt to 
keep the lung structure as intact as possible. So collagen 
deposition must not be viewed as a late response to 
abnormal healing, but as an early phenomenon. Some 
experimental studies corroborate this early onset of 
collagen deposition [3]. Moreover, patients show an 
increase in procollagen levels in the ﬁ rst 48 hours after 
meeting ALI criteria [4].
Tissue repair involves a variety of mechanisms includ-
ing edema reabsorption, resolution of inﬂ amma tion and 
cell proliferation in order to repopulate the alveolar 
epithelium (Figure 1c). Lung edema clearance is a crucial 
step. It has been documented that mild alveolar injury 
results in increased alveolar ﬂ uid reabsorption. However, 
in severe cases, the injured pneumocytes cannot sustain 
the active transport of ions and water across the epi the-
lium. Th erefore, cell integrity is essential for edema 
clearance. Th e molecular mechanisms of ion and water 
transport in lung exceed the scope of this article, and 
have been reviewed elsewhere [5]. Regulation of the 
inﬂ ammatory response is a complex mechanism that 
requires interplay between several immune mediators 
[6]. Some anti-inﬂ ammatory cytokines, IL-10 being the 
most studied, are released even during a pro-inﬂ amma-
tory response as a negative feedback mechanism. When 
the pro-inﬂ ammatory pathways are downregulated (i.e., 
after cessation of the stimulus), these anti-inﬂ ammatory 
mediators decrease cytokine expression. Apoptosis of 
inﬂ am matory cells (mainly neutrophils) has also been 
documented when pro-survival signals, such as granulo-
cyte-colony stimulating factor (G-CSF), disappear. 
Alveolar macrophages also play a role in this phase 
engulﬁ ng death cells.
Finally, the regeneration of the alveolar structure 
requires the proliferation and diﬀ erentiation of some 
progenitors into type I pneumocytes (Figure 2). Diﬀ erent 
growth factors (e.g. epidermic [EGF], keratinocyte [KGF] 
or hepatic growth factor [HGF]), acting through tyrosin-
kinase receptors, promote cell proliferation. Th e cell lines 
implicated in this step are a matter of research, stimulated 
by the growing interest in stem cells and regenerative 
medicine [7]. Endogenous progenitor cells include both 
resident stem cells and bone marrow-derived cells. 
Regarding the ﬁ rst, type II pneumocytes proliferate after 
injury and can originate type I cells. Th is has been 
demonstrated after pneumonectomy, hyperoxia or 
repeated bleomycin instillation in mice. Moreover, bone 
marrow-derived stem cells could also participate in 
alveolar repair, although data on the engraftment and 
diﬀ erentiation of these cells are more focused on their 
therapeutic use than to clarify their role in the normal 
repair process. In addition, other cell types may also play 
Figure 1. Overview of the injury and repair mechanisms in an alveolus. (a) The normal alveolus is formed by type I and type II alveolar cells. 
The former cover the majority of the alveolar area, and the latter are reduced in number. (b) After acute lung injury, the infl ammatory response 
results in the recruitment of neutrophils from the circulation, the development of alveolar edema and the deposition of collagen fi bers. The necrotic 
alveolar cells are detached from the basement membrane. (c) During the repair phase, the alveolar fl uid is reabsorbed, the infl ammatory response 
attenuated, and type II alveolar cells (among others) proliferate and diff erentiate into type I pneumocytes. In this phase, collagen fi bers may 
facilitate cellular migration. (d) Finally, digestion of the collagen scar is needed for complete normalization of lung functions.
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a role in alveolar regeneration. Lung mesenchymal cells 
are activated after ALI and, in addition to collagen 
synthesis, they may secrete growth factors and even 
modu late the immune response by secreting anti-
inﬂ ammatory cytokines [8].
Th e previously formed collagen scar can facilitate cell 
attachment to keep the alveolar structure. Again, collagen 
synthesis should be viewed as part of the normal healing 
process. However, excessive collagen deposition may 
impair gas exchange and lung mechanics. So, in order to 
restore normal respiratory function, the previously 
formed scar must be processed and removed (Figure 1d). 
Th is can be carried out by matrix metalloproteinases 
(MMPs), a family of enzymes that can digest virtually all 
types of extracellular ﬁ bers [9]. One of the most impor-
tant sources of MMPs is inﬂ ammatory cells (neutrophils 
and macrophages contain signiﬁ cant amounts of MMP-8 
and MMP-9). Th erefore, it can be hypothesized that the 
inﬂ ammatory response is important for adequate lung 
repair, and that MMPs are one of the links between these 
two phenomena. Th e underlying mechanisms that 
regulate this step in ALI are unknown, but knowledge of 
these mechanisms could help clarify why some patients 
develop a severe ﬁ brotic response, which can cause long-
term disabilities.
The special case of repair after ventilator-induced 
lung injury
Ventilation with high tidal volumes or transpulmonary 
pressures may cause severe injury to the lungs. In experi-
mental models, there is a clear causality relation ship 
between ventilatory settings and so-called ventilator-
induced lung injury (VILI). Although this relationship is 
less clear in patients, especially those with previous ALI, 
the development of ventilatory strategies aimed to avoid 
further lung injury has been shown to decrease mortality. 
Th erefore, although experimental models of VILI cannot 
be directly extrapolated to critically ill patients, they 
highlight the mechanisms of injury and repair involved.
A few studies have focused on repair after VILI, giving 
some insights into this process. Th e ﬁ rst was published 
by Nin et al. in 2008 [10]. Th ese authors submitted 
Sprague-Dawley rats to injurious ventilation for one hour, 
reestablishing spontaneous breathing and letting them 
recover. Histological studies showed a signiﬁ cant reduc-
tion in capillary congestion, interstitial edema, type-I 
pneumocyte necrosis and hyaline membrane formation 
after 24 hours of recovery, reaching normality after 
72 hours. Inﬂ ammatory markers showed a similar pattern. 
Aortic vascular and pulmonary microvessel res ponses to 
acetylcholine and norepinephrine were impaired and 
returned to normal at 168 and 72 hours respectively. Th is 
study demonstrated that VILI can revert rapidly after 
spontaneous breathing is reestablished.
In another study, Gonzalez-Lopez et al. [11] submitted 
CD1 mice to a combination of two ventilator strategies. 
One group was ventilated for 90  minutes with high 
pressures and another group was ventilated with the 
same strategy followed by up to 4  hours of protective 
ventilation. Histological score, pulmonary edema, alveolar 
permeability and tumor necrosis factor (TNF)-α increased 
during injury and returned to baseline values during 
repair. Later comparisons of the repair phase showed that 
survivors had higher pneumocyte proliferation and 
leukocyte inﬁ ltration and lower alveolar permeability and 
collagen content than non-survivors. MMP-2 levels were 
also increased in survivors. Th is MMP improves wound 
healing in ex vivo models using mice and human alveolar 
epithelial cell lines. Taken together, these studies suggest 
that an appropriate inﬂ ammatory response and tissue 
remodeling are key events during repair.
The role of infl ammation in tissue damage and 
repair
Inﬂ ammation is necessary for the development of a 
proper response to the insult, but it can damage the 
tissue where it takes place. Inﬂ ammation leads initially to 
an alteration in homeostasis, during which tissue partially 
Figure 2. Cell proliferation in control mice (a) and during the repair phase after ventilator-induced lung injury (b). Some cells (arrows) show 
positive staining for Ki-67, a marker of cell proliferation.
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sacriﬁ ces cellular and extracellular matrix integrity and 
tissue functionality for the beneﬁ t of a quick response. A 
good example of this compromise is the early recruitment 
of immune cells to the site of injury. Th e ﬁ rst cells 
arriving are neutrophils [12]. Representing 70% of total 
circulating leukocytes, these cells are rapid responders to 
chemokines, appearing in the lungs a few minutes after 
initial injury. But this recruitment has a price for lung 
integrity; after migrating through endothelial cells and 
before arriving in the alveolar space, leukocytes ﬁ nd the 
basement membrane, a highly organized extracellular 
matrix mainly composed of four families of glycoproteins 
(laminin, collagen type IV isoforms, nidogen and heparan 
sulfate proteoglycans). Th e basement membrane is 
actively involved in leukocyte recruitment by its potential 
to bind and release cytokines and chemotactic factors. 
Th e only way neutrophils can cross this barrier is by 
proteolytic degradation [13], contributing to further 
damage of lung structure. Once in the lung, the release of 
a variety of alarmins, free oxygen radicals, leukotrienes, 
proteases and other pro-inﬂ ammatory molecules 
maintain the inﬂ ammatory state, thereby contributing to 
the ALI phase.
Th e role of proteases, especially of MMPs, in the 
pathogenesis of ALI has been controversial. Extracellular 
matrix processing releases some bioactive molecules. For 
example, type I collagen degradation generates an acety-
lated tripeptide with similar chemotactic activity to IL-8 
[14]; moreover, MMPs process many immune mediators, 
like pro- and anti-inﬂ ammatory cytokines and chemo-
kines, altering their activity (e.g., IL-1β, transforming 
growth factor [TGF]β and lipopolysaccharide-induced 
CXC chemokine [LIX] activation and macrophage inﬂ am-
matory protein [MIP]-1α inactivation) and bioavailability 
(TNF-α and TGFβ release from cell surface and extra-
cellular matrix, respectively) [15]. Th eir ability to regulate 
the inﬂ ammatory mediators and degrade collagen ﬁ bers 
also makes MMPs key elements in the later stages of 
inﬂ ammation, when resolution and repair of the injured 
tissue are of paramount importance. In a model of liver 
injury, it has been demonstrated that neutropenic 
animals develop more severe ﬁ brosis, probably due to the 
lack of MMPs (released by neutrophils) in the repair 
phase [16]. A similar dependence between inﬂ ammation 
and collagenolysis in the lung has not been demonstrated, 
but these ﬁ ndings warrant more research.
Research on models of lung injury using knock-out 
mice for single MMPs, such as MMP-2, MMP-3, MMP-7, 
MMP-8 and MMP-9, has shed some light on this issue. 
MMP-2 [11], MMP-7 [17] and MMP-9 [18] have been 
shown to be involved in alveolar epithelial repair in 
experi mental models of wound healing. Furthermore, a 
model of VILI [19] demonstrated that MMP-9 function is 
worth preserving, given that mice deﬁ cient in this 
protease had increased levels of lung injury. On the other 
hand, MMP-3 may be detrimental, as mice lacking this 
MMP were protected against lung injury caused by 
administration of nonspeciﬁ c IgG [20] or bleomycin [21]. 
Regarding MMP-8, this protease has shown diﬀ erent 
eﬀ ects depending on the experimental model. It has a 
detrimental role in models of VILI [22] and lung ﬁ brosis, 
due to IL-10 cleavage [23]. However, this enzyme may be 
beneﬁ cial after lipopolysaccharide (LPS) or hyperoxia 
exposition [24]. Moreover, it may have a role in resolution 
stages of ALI, as it seems to be involved in neutrophil 
apoptosis through modulation of IL-4 levels [25].
Th erefore, this complex family serves not only to regu-
late the inﬂ ux and clearance of leukocytes and the 
inﬂ ammatory process itself, but also the removal of 
excess deposits of collagen ﬁ bers released by ﬁ broblasts 
during ALI. It is becoming clearer that pharmacotherapy 
should be aimed at blocking speciﬁ c MMPs during the 
early stages of ALI, in order to avoid destruction of the 
basement membrane and extracellular matrix caused by 
their proteolytic action. Although this could have an 
initial beneﬁ t it may turn detrimental to the repair 
process if treatment is continued.
Signs of tissue repair in patients
Th e assessment of lung repair in patients could be of 
great interest because of its prognostic relevance in ALI 
patients. However, measurement of any mediator 
involved in tissue repair has one fundamental limitation: 
If a patient shows high levels of a given marker, it could 
be due to ongoing repair and, therefore, associated with a 
good prognosis. However, the same high levels could also 
be due to massive injury triggering a full-blown response. 
In this case, the outcome may not be so good.
Collagen levels illustrate this two-sided interpretation 
of biomarkers. As mentioned before, collagen deposition 
is an early event during ALI. Increased levels of pro-
collagen in pulmonary edema ﬂ uid may have a prognostic 
signiﬁ cance in patients with ALI. For instance, Chesnutt 
et al. [26] reported that a procollagen concentration 
above 1.75 U/ml had a positive predictive value for death 
of 0.75. However, a recent article by Quesnel et al. [27] 
showed that patients with ALI/acute respiratory distress 
syndrome (ARDS) with ﬁ broblasts in their alveolar ﬂ uid 
had increased levels of type I procollagen, a decreased 
pro-inﬂ ammatory response (lower neutrophil count, 
decreased IL-8 levels), and improved prognosis, suggest-
ing a switch from inﬂ ammation and tissue destruction to 
alveolar repair.
Research on the prognostic value of MMP-9 has 
yielded similar conﬂ icting results. Abundance of this 
protease in bronchoalveolar lavage (BAL) ﬂ uid has been 
related to a worse outcome. However, MMP-9 has shown 
a protective role in experimental models of lung injury 
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[19,28], and a clinical study demonstrated that this 
enzyme could have therapeutic value (see below). Finally, 
the prognostic value of growth factors in ALI was 
addressed years ago by Verghese et al. [29]. Lower levels 
of HGF and KGF were found in survivors. Although these 
mediators promote cell proliferation, diﬀ erentiation and, 
ultimately, alveolar repair, their presence reﬂ ects a worse 
outcome. But, as the authors of the article discussed, the 
increased levels in non-survivors may be a marker of 
more severe injury.
Collectively, published results suggest that measure-
ment of a single biomarker in patients can be misleading, 
as it can reﬂ ect both the severity of the injury and the 
subsequent healing process. An accurate prediction may 
require complex reasoning that takes into account the 
initial conditions but also the host’s biological response. 
Th erefore, an approach based on multiple markers could 
oﬀ er an alternative to monitor the course of this disease 
in patients.
Therapeutic strategies aimed at lung repair
Since identiﬁ cation of the pathways involved in lung 
injury, most literature has been focused on the use of 
therapies aimed at reducing ALI by truncating the 
inﬂ am matory response. Unfortunately, none of these 
strategies has been successfully applied in the clinical 
practice. Recently, a signiﬁ cant number of studies have 
centered their eﬀ orts on enhancing the repair process 
using diﬀ erent approaches, ranging from the use of bio-
compatible materials or cells to the therapeutic use of 
mediators aimed at promoting cell proliferation, migra-
tion and diﬀ erentiation. Figure 3 summarizes the diﬀ er-
ent therapeutic targets aimed at favoring lung repair.
In many cases, these studies are still at the in vitro 
stages, such as the use of vimentin to improve wound 
repair [30], or just suggest a possible beneﬁ cial role (e.g., 
connexins [31], adrenomedullin [32] or a possible modu-
lation of the transcription factors, FoxM1 and Runx3 
[33,34]) and need further research to prove their viability 
in vivo. Improvement of plasma membrane repair is a 
possible direct treatment. A recent study in an ex vivo 
model using an amphiphilic macromolecule (Poloxamer 
188) with sealing properties showed signs of membrane 
repair in alveolar resident cells and an improvement in 
conventional measures of lung injury [35].
Enhancement of the epithelial repopulation is a 
promising therapeutic target that could be achieved in 
diﬀ erent ways. In recent years, therapy using stem cells is 
gaining considerable interest. It has been demonstrated 
that these cells are active players in lung repair [36]. In 
spite of doubts about their safety and the best adminis-
tration route to improve their engraftment, use of stem 
cells in animal models has been demonstrated to 
attenuate damage and ﬁ brosis in lungs challenged with 
endotoxin [37]. In a recent study, Curley et al. [38] 
submitted a group of rats to VILI followed by an 
intravenous injection of mesenchymal stem cells; these 
animals showed less lung injury and increased levels of 
the anti-inﬂ ammatory and anti-ﬁ brotic cytokine, IL-10, 
than did rats who did not receive the stem cells. Th e 
speciﬁ c mechanisms by which stem cells perform their 
functions in tissue repair are still under study, but the 
release of several growth factors and the suppression of 
pro-inﬂ ammatory cytokines seem to be involved.
An alternative approach is the therapeutic use of 
exogenous growth factors to induce the proliferation of 
endogenous stem cells. Among these factors, EGF, KGF 
and HGF have been the most studied. All of them are 
mitogens in type II pneumocytes, and act synergistically 
to mediate their maturation and increase surfactant 
synthesis [8]. EGF had beneﬁ cial eﬀ ects in an animal 
model of ALI [39], and inhibition of EGF receptor had a 
Figure 3. Therapeutic approaches to promote lung repair. (a) Direct repair of the plasma membrane could be achieved using amphipathic 
compounds that seal injured membranes. (b) Exogenous stem cells to repair the denuded areas. (c) Administration of growth factors to stimulate 
the proliferation of endogenous stem cells. (d) Stimulation or (e) selective blockade of diff erent matrix metalloproteinases (MMPs) to promote 
collagen processing or avoid the adverse eff ects of these enzymes.
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detrimental eﬀ ect during airway epithelium repair [40]. 
KGF has been linked to upregulation of anti-inﬂ am ma-
tory cytokines and modulation of epithelial cell migration 
[41]. In the same way, HGF attenuates inﬂ ammation and 
showed antiﬁ brotic eﬀ ects in a murine model of 
bleomycin-induced ﬁ brosis [42]. Vascular endothelial 
growth factor (VEGF) could also have a therapeutic eﬀ ect 
by its ability to repair damaged endothelium, therefore 
helping in clearance of lung edema, but animal models 
have shown disappointing results [43].
Finally, manipulation of tissue remodeling could 
improve the outcome of ALI patients by favoring re-
epithelization or avoiding ﬁ brosis. Th e use of steroids in 
ALI has yielded conﬂ icting results, depending on the 
time of application. Th ese discrepancies can be explained 
if one takes into account the beneﬁ cial eﬀ ects of 
inﬂ ammation during the repair phase discussed earlier. 
However, no study has speciﬁ cally addressed the eﬀ ects 
of steroids during lung repair.
MMPs are alternative targets to promote repair. Non-
selective MMP inhibitors are available, but the lack of 
speciﬁ city could limit their beneﬁ ts and none of them has 
been tested in ALI. Selective blockade or stimulation 
(depending on the role of the MMP and timing) could be 
a more promising approach. One of the ﬁ rst examples 
that has arrived in human trials is the use of beta-2 
adrenergic receptor agonists. Intravenous administration 
of salbutamol decreased the duration and severity of lung 
injury by reducing lung edema in patients with ARDS 
[44]. Th is ﬁ nding was associated with an upregulation of 
MMP-9 [18] and, therefore, with better alveolar epithelial 
repair [45]. Nevertheless, the route of administration 
could be relevant, as a recent trial has concluded that 
patients with ALI treated with inhaled salbutamol show 
no signiﬁ cant improvement in clinical outcomes [46]. On 
the other hand, blockade of MMP-8 has shown beneﬁ cial 
eﬀ ects in experimental models of lung injury [22], 
including decreased lung ﬁ brosis after bleomycin 
administration [23]. However, no clinical study aimed at 
modulating this protease has yet been proposed.
Conclusion
Th e lungs have a substantial potential for recovery after 
ALI. Of note, the mechanisms that can cause tissue 
disruption in the early phase also contribute to its repair 
later on, inﬂ ammation and matrix remodeling being 
paradigmatic examples. Th erefore, therapies that disrupt 
these pathways, such as MMP inhibition, may have a 
prophylactic value, but their application at a later phase 
could be detrimental. Knowledge of the mediators 
involved in tissue repair could lead to new therapeutic 
strategies being applied after the initial insult has been 
controlled. Growth factors, exogenous stem cells 
(including type II pneumocytes) or drugs that promote 
matrix remodeling could be new alternatives to improve 
the prognosis of patients with ALI.
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